Tianli Biotech
- Biotech or pharma, therapeutic R&D
TianLi Biotech is a clinical stage biotech with a mission to develop innovative, safe, well-tolerated and effective inhaled and orally available drugs that alleviate suffering of patients with debilitating/fatal respiratory conditions, with IPF being the initial focus. TianLi Biotech is a Melbourne-based spin-out company founded in 2019 as joint venture between The University of Melbourne and Beijing No.1 Biotechnology Group Co., Ltd. The company leveraged the ground-breaking discovery that isoforms delta and epsilon of casein kinase 1 (CK1δ/ε) modulate fibrosis and inflammation, into drug developments for conditions in which fibrosis and inflammation are the main features. The company has a follow-on program with orally available inhibitors with systemic anti-fibrotic and anti-inflammatory activity.
)
)
){kind=logo}
){kind=logo}
){kind=logo}